CRISPR Therapeutics (CRSP) Promotes Andrew Silver To CFO As Raju Prasad Resigns

What happened: CRISPR Therapeutics (NasdaqGM:CRSP) promoted Andrew J. Silver to Chief Financial Officer, effective October 19, 2026. Outgoing CFO Raju Prasad, Ph.D., resigned from his role, also effective October 19, 2026. Key numbers: Effective date October 19, 2026. Market cap $4.8b. Cash US$2.4b. Fair value cited at $87.56. Why it matters: The article ties the CFO seat to funding discipline, citing analyst focus on late-stage execution for CTX310, CTX611 and zugo-cel and on dilution risk if capital raising accelerates. Market: -1.2% today ($49.39), -8.1% YTD, 1.3x vol — as of 22:46 UTC

CRISPR Therapeutics (NasdaqGM:CRSP) promoted Andrew J. Silver to Chief Financial Officer, effective October 19, 2026. Outgoing CFO Raju Prasad, Ph.D., resigned from his role, also effective October 19, 2026.

The article ties the CFO seat to funding discipline, citing analyst focus on late-stage execution for CTX310, CTX611 and zugo-cel and on dilution risk if capital raising accelerates. Market: -1.2% today ($49.39), -8.1% YTD, 1.3x vol — as of 22:46 UTC